Sionna Therapeutics Inc. (SION) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Sionna Therapeutics Inc. (NASDAQ: SION) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.87 (-3.25% 1D, market cap $180.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SION ranks #580 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SION carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, UPB (Upstream Bio Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $179.1M) and ADAG (Adagene Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.0M). Among the 5-stock peer group, SION leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).
Per SION's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002036042), Sionna Therapeutics Inc. generated $0 in revenue, -$75.3M in net income, and -$66.7M in free cash flow against $326.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 29.4 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While SION currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.41) and Max Pain ($4.06) forces dealer call-delta covering toward $57.72.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Sionna Therapeutics Inc. (SION) dropped -3.25% to $3.87, trading at 2% of its 52-week range ($3.55 – $54.97). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
The Clinical Trial Vanguard report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Investing.com South Africa report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SION today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SION. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Sionna Therapeutics Inc. (SION) ranks #580 by composite RQD confidence (38/100, grade D-) and #589 by equity capitalization ($180.8M). Within this direct 5-issuer industry benchmark cohort, SION leads on earnings valuation at N/A trailing P/E, while ORMP leads on capital efficiency and profitability with -7.8% ROIC and 0.7% gross margin. ANTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with SION at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SION
ACTIVE
Sionna Therapeutics Inc. | D- | 38/100 | — | — | -28.3% | -3.25% | $180.8M | Benchmark Subject |
| UPB Upstream Bio Inc. | D- | 42/100 | — | — | -35.0% | +4.28% | $179.1M | /upb-vs-sion → |
| ADAG Adagene Inc. | E | 30/100 | — | — | -35.0% | -6.34% | $177.0M | /adag-vs-sion → |
| ANTX AN2 Therapeutics Inc. | D | 46/100 | — | — | -35.0% | -3.41% | $177.0M | /antx-vs-sion → |
| ORMP Oramed Pharmaceuticals Inc. | D- | 41/100 | — | 0.7% | -7.8% | -2.84% | $176.0M | /ormp-vs-sion → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sionna Therapeutics Inc. (SION) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$75.3M, operating cash flow of -$66.3M, and free cash flow of -$66.7M (-26.2% YoY). On the balance sheet, SION closed FY2025 with $326.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$75.3M | -$66.3M | -$66.7M | $326.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$61.7M | -$52.8M | -$52.8M | $185.8M | — |
As of 2026-11-02, Sionna Therapeutics Inc. (NASDAQ: SION) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.87 (-3.25% 1D, market cap $180.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SION ranks #580 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SION carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, UPB (Upstream Bio Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $179.1M) and ADAG (Adagene Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.0M). Among the 5-stock peer group, SION leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).
Per SION's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002036042), Sionna Therapeutics Inc. generated $0 in revenue, -$75.3M in net income, and -$66.7M in free cash flow against $326.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SION last traded at $3.87 (-3.25% on volume of 534,393 shares), positioning the stock -28.47% below its 50-day simple moving average ($5.41) and -87.07% below its 200-day simple moving average ($29.93). Across its 52-week range of $3.55 to $54.97, SION sits at the 0.6% percentile with a 14-day RSI of 29.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.39 to $4.35).
Why SION Stock dropped -3.25% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, SION scores 38 out of 100, a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 7/20 (ROIC -28.3%; FCF yield 0%), indicating the company is not generating cash from operations and is consuming capital. Whale 13F Flow scores 6/20 (institutional accumulation and options positioning), a weak reading on institutional conviction. Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), the lowest pillar, signaling limited insider-side confidence in the data provided. Macro Regime Fit scores 10/20 (Beta 1.0; sector sensitivity), a middling reading. Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), a mixed picture: leverage appears moderate, but the Piotroski reading is weak.
Taken together, the pillars describe an issuer with no reported revenue, sustained operating losses, and negative free cash flow, offset partly by a balance sheet that the source data does not show as acutely stressed. Potential upside drivers, as framed by the news wire, center on pipeline and conference-related developments; these are event-dependent and are not quantified in the source data. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in source data, and the RQD score reflects the absence of cash generation. Investors weighing this profile should note that the rating is a rules-based score derived from the supplied inputs, not a forecast of price direction.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-89.0M | $-75.3M | N/A | $-66.7M | $58.5M | N/A |
| FY 2024 | $0.0M | $-70.6M | $-61.7M | N/A | $-52.8M | $37.8M | N/A |
Per the SEC financials, reported revenue is $0.0M in both periods, and operating losses widened from $-70.6M to $-89.0M. Per market data, gross, operating, and net margins are each 0%, and ROIC is -28.3%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the forensic balance sheet pillar of the RQD rating. Reported cash rose from $37.8M to $58.5M, and Debt/Equity is 0.5, while the period-level Debt field is N/A in the source data.
Per the recent news feed (six items, all tagged to SION):
All news items carry a YELLOW light and a MARKET WIRE impact label. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Sionna Therapeutics Inc. (SION) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
The Clinical Trial Vanguard report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Investing.com South Africa report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Welcome to the SION (Sionna Therapeutics Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SION, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Sionna Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SION, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.00 (52-wk range $3.69 - $4.57), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).